Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomized, 26-week, treat-to-target trial in insulin naïve patients with type 2 diabetes - Gough, S C; Bode, B; Woo, V (Lancet Diabetes Endocrinol, 2014)
NN9068-3697 (DUAL-I) trial investigators.